Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Usefulness of quantitative assessment of the WT1 gene transcript as a marker for minimal residual disease detection

30 Jun 2003

Abstract excerpt

The usefulness of the WT1 quantitative assessment by real-time quantitative polymerase chain reaction (RQ-PCR) as a marker for minimal residual disease (MRD) detection after allogeneic bone marrow transplantation (BMT) has been reported in a recent issue of Blood by Ogawa et al[1][1] in a series of

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Prenatal Screening and Diagnostics
Share to Renal and related cancers

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 12835231
DOI: 10.1182/blood-2003-03-0980

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Usefulness of quantitative assessment of the WT1 gene transcript as a marker for minimal residual disease detectionPMID 12835231Read ↗

Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patientsSemantic proximity Read ↗

Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometrySemantic proximity Read ↗

WT1 as a Universal Marker for Minimal Residual Disease Detection and Quantification in Myeloid Leukemias and in Myelodysplastic SyndromeSemantic proximity Read ↗

Monitoring Minimal Residual Disease in Leukemia Using Real-time Quantitative Polymerase Chain Reaction for Wilms Tumor Gene (WT1)Semantic proximity Read ↗

Molecular methods used for detection of minimal residual disease following hematopoietic stem cell transplantation in myeloid disorders.Semantic proximity Read ↗

MRD assessed byWT1andNPM1transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicinSemantic proximity Read ↗

Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targetsSemantic proximity Read ↗

Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR dataSemantic proximity Read ↗

Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter studySemantic proximity Read ↗

Quantitative monitoring of single nucleotide mutations by allele-specific quantitative PCR can be used for the assessment of minimal residual disease in patients with hematological malignancies throughout their clinical course.Semantic proximity Read ↗

Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspectsSemantic proximity Read ↗

Prognostic impact of WT1 expression prior to hematopoietic stem cell transplantation in children with malignant hematological diseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.